Last reviewed · How we verify
QuantumLeap Healthcare Collaborative — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
13 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Pertuzumab and Trastuzumab | Pertuzumab and Trastuzumab | marketed | HER2-targeted monoclonal antibody combination | HER2 (human epidermal growth factor receptor 2) | Oncology |
Therapeutic area mix
- Oncology · 6
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- European Organisation for Research and Treatment of Cancer - EORTC · 2 shared drug classes
- Hoffmann-La Roche · 2 shared drug classes
- Bristol-Myers Squibb · 2 shared drug classes
- Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
- HK inno.N Corporation · 2 shared drug classes
- Amgen · 2 shared drug classes
- Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
- Hospices Civils de Lyon · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for QuantumLeap Healthcare Collaborative:
- QuantumLeap Healthcare Collaborative pipeline updates — RSS
- QuantumLeap Healthcare Collaborative pipeline updates — Atom
- QuantumLeap Healthcare Collaborative pipeline updates — JSON
Cite this brief
Drug Landscape (2026). QuantumLeap Healthcare Collaborative — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/quantumleap-healthcare-collaborative. Accessed 2026-05-16.